The missing layer

There's a quiet stretch in Australian medical research that we don't talk about enough.

It's the Valley of Death, the long, uncertain journey where a discovery has to become something a company can carry forward. And it's where most of our brilliant science gets stuck.

Australian medical research charities do extraordinary work. They fund the brilliant PhD student. They build the hospital wing. But that stretch in the middle, between the lab bench and the clinic, is the bit we've collectively been leaving alone.

This is where venture philanthropy comes in, and where charities are uniquely placed to lead.

It's patient capital with a mission at its heart. No institutional conflicts. A higher risk tolerance than a traditional VC, because the goal is impact as well as returns. It can support the technical work commercial investors aren't ready for yet, and when those bets pay off, the proceeds come home to fund the next discovery.

The international story is genuinely inspiring. The US Cystic Fibrosis Foundation invested around $150M into a small biotech called Vertex. In 2014 it sold the royalty rights for $3.3B, money that now funds its mission indefinitely. A charity, funding its own future, through the science it believed in.

And the good news is, Australian organisations are already showing this can work here.

AusHealth Ventures has quietly invested $50M+ into medical research since 1985, including oncology biotechs like FivepHusion.

Minderoo's Tenmile is running a $250M healthcare venture fund, co-investing alongside commercial VCs.

Snow Medical has committed $24M to long-horizon translational fellowships, designed for the patience that real translation requires.

Three different organisations. Three different models. The same underlying belief: that charitable capital, deployed with patience and discipline, can do something grants alone never will.

We don't just need more money in Australian research. We need capital as ambitious as the science it supports, and as committed as the people who fund it.

The first movers have shown the way. I'd love to see who joins them next.

Where Apex Science helps

If your charity is weighing how to support the middle of the pipeline, a Program Decision Session is a good place to start. Fractional Chief Scientific Advisor support can then carry that investment discipline over time. See services and pricing, or book a 30-minute call.

First published on LinkedIn as part of the #TheCompleteTranslationPipeline series.